1
|
Lee KN, Neibart SS, Droznin A, Guthier CV, Martin NE, Mancias JD, Lam M, Shiloh R, Peng LC, Ng K, Surana R, Enzinger P, Meyerhardt J, Mamon HJ. A Single-Institution Experience of Acute Neuropathic Lumbosacral Pain in Patients Treated with Short Course Hypofractionated Radiotherapy in Locally Advanced Rectal Cancer. Int J Radiat Oncol Biol Phys 2023; 117:e312-e313. [PMID: 37785125 DOI: 10.1016/j.ijrobp.2023.06.2341] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) There has been increased interest in the use of short course hypofractionated radiotherapy as part of a total neoadjuvant treatment (TNT) approach in the management of rectal cancer since publication of the RAPIDO trial. However, the literature on short course radiation for rectal cancer has not reported significant acute toxicities in the weeks immediately following the completion of treatment. Anecdotally, a subset of patients has experienced acute neuropathic pain characterized in a lumbosacral distribution. This study investigates acute lumbosacral toxicity for patients receiving hypofractionated short course radiation as part of their definitive treatment for rectal cancer. MATERIALS/METHODS We retrospectively analyzed 75 patients with locally advanced rectal adenocarcinoma treated with hypofractionated short course radiation (25 Gy in 5 fractions) at our institution between 2016 and 2022. Acute toxicity caused by radiation was defined as that occurring from the start of radiation treatment to either 30 days post radiation completion, the start of chemotherapy, or date of surgery, whichever occurred first. RESULTS Among 75 patients treated with hypofractionated short course preoperative radiation with definitive intent, we identified 10 patients (13.3%) who experienced significant lumbosacral neuropathic pain and initiated a report to their medical providers during the acute toxicity time frame. Commonly, this was described as an achy pain in the bilateral buttocks radiating down to the knees or posterior claves. Patients rated this pain between moderate to extreme and management included steroids after failure of improvement with conservative measures, gabapentin, and conservative treatment with NSAIDs and Tylenol. Average time to onset of acute lumbosacral neuropathic pain was 3.7 days (SD 2.05) from start of RT. CONCLUSION We have identified a previously underappreciated acute toxicity of neuropathic lumbosacral pain in short course hypofractionated radiation therapy, which may be due to a lumbosacral plexus toxicity. Further analysis will seek to identify predictive factors such as comorbidities and dose to the lumbosacral plexus, and to determine whether there is a correlation between these observed acute toxicities and long-term outcomes.
Collapse
Affiliation(s)
- K N Lee
- Harvard Radiation Oncology Program, Boston, MA
| | - S S Neibart
- Department of Medicine, Brigham and Women's Hospital, Boston, MA
| | - A Droznin
- Brigham and Women's Hospital/ Dana Farber Cancer Institute, Boston, MA
| | - C V Guthier
- Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
| | - N E Martin
- Department of Radiation Oncology, Brigham and Women's Hospital, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA
| | - J D Mancias
- Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham & Women's Hospital, Boston, MA
| | - M Lam
- Dana Farber Cancer Institute / Brigham & Women's Hospital, Boston, MA
| | - R Shiloh
- Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham & Women's Hospital, Boston, MA
| | - L C Peng
- Department of Radiation Oncology, Dana-Farber Brigham Cancer Center, Boston, MA
| | - K Ng
- Dana Farber Cancer Institute, Boston, MA
| | - R Surana
- Dana Farber Cancer Institute, Boston, MA
| | - P Enzinger
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
| | | | - H J Mamon
- Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, MA
| |
Collapse
|
2
|
Shiloh R, Chlouba T, Hommelhoff P. Quantum-Coherent Light-Electron Interaction in a Scanning Electron Microscope. Phys Rev Lett 2022; 128:235301. [PMID: 35749196 DOI: 10.1103/physrevlett.128.235301] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/10/2021] [Revised: 01/21/2022] [Accepted: 03/29/2022] [Indexed: 06/15/2023]
Abstract
The last two decades experimentally affirmed the quantum nature of free electron wave packets by the rapid development of transmission electron microscopes into ultrafast, quantum-coherent systems. So far, all experiments were restricted to the bounds of transmission electron microscopes enabling one or two photon-electron interaction sites. We show the quantum coherent coupling between electrons and light in a scanning electron microscope, at unprecedentedly low, subrelativistic energies down to 10.4 keV. These microscopes not only afford the yet-unexplored energies from ∼0.5 to 30 keV providing the optimum electron-light coupling efficiency, but also offer spacious and easily configurable experimental chambers for extended, cascaded optical set ups, potentially boasting thousands of photon-electron interaction sites. Our results make possible experiments in electron wave packet shaping, quantum computing, and spectral imaging with low-energy electrons.
Collapse
Affiliation(s)
- R Shiloh
- Physics Department, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Staudtstraße 1, 91058 Erlangen, Germany
| | - T Chlouba
- Physics Department, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Staudtstraße 1, 91058 Erlangen, Germany
| | - P Hommelhoff
- Physics Department, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Staudtstraße 1, 91058 Erlangen, Germany
| |
Collapse
|
3
|
Shiloh R, Illmer J, Chlouba T, Yousefi P, Schönenberger N, Niedermayer U, Mittelbach A, Hommelhoff P. Electron phase-space control in photonic chip-based particle acceleration. Nature 2021; 597:498-502. [PMID: 34552256 DOI: 10.1038/s41586-021-03812-9] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2021] [Accepted: 07/07/2021] [Indexed: 11/09/2022]
Abstract
Particle accelerators are essential tools in science, hospitals and industry1-6. Yet their costs and large footprint, ranging in length from metres to several kilometres, limit their use. The recently demonstrated nanophotonics-based acceleration of charged particles can reduce the cost and size of these accelerators by orders of magnitude7-9. In this approach, a carefully designed nanostructure transfers energy from laser light to the particles in a phase-synchronous manner, accelerating them. To accelerate particles to the megaelectronvolt range and beyond, with minimal particle loss10,11, the particle beam needs to be confined over extended distances, but the necessary control of the electron beam's phase space has been elusive. Here we demonstrate complex electron phase-space control at optical frequencies in the 225-nanometre narrow channel of a silicon-based photonic nanostructure that is 77.7 micrometres long. In particular, we experimentally show alternating phase focusing10-13, a particle propagation scheme for minimal-loss transport that could, in principle, be arbitrarily long. We expect this work to enable megaelectronvolt electron-beam generation on a photonic chip, with potential for applications in radiotherapy and compact light sources9, and other forms of electron phase-space control resulting in narrow energy or zeptosecond-bunched beams14-16.
Collapse
Affiliation(s)
- R Shiloh
- Physics Department, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
| | - J Illmer
- Physics Department, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
| | - T Chlouba
- Physics Department, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany
| | - P Yousefi
- Physics Department, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany
| | - N Schönenberger
- Physics Department, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.,Max Planck Institute for the Science of Light, Erlangen, Germany
| | - U Niedermayer
- Technische Universität Darmstadt, Institute for Accelerator Science and Electromagnetic Fields (TEMF), Darmstadt, Germany
| | - A Mittelbach
- Physics Department, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany
| | - P Hommelhoff
- Physics Department, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany. .,Max Planck Institute for the Science of Light, Erlangen, Germany.
| |
Collapse
|
4
|
Shiloh R, Chlouba T, Yousefi P, Hommelhoff P. Particle acceleration using top-illuminated nanophotonic dielectric structures. Opt Express 2021; 29:14403-14411. [PMID: 33985164 DOI: 10.1364/oe.420235] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/21/2021] [Accepted: 03/22/2021] [Indexed: 06/12/2023]
Abstract
In dielectric laser acceleration, nanostructures etched into silicon are used to convert free-space ultrashort laser pulses, incident from the side and parallel to the wafer substrate, to accelerate particles. This current approach is experimentally challenging and, as it turns out, not quite necessary for most experiments and practical applications. Here, we experimentally demonstrate and numerically verify the efficacy of top-illuminated structures, and measure a maximum acceleration gradient of 49.2 ± 3.1 MeV/m. We discuss how, in practice, this approach proves superior to the current standard in the field, and expect it to become the definitive choice for nanophotonic particle laser acceleration.
Collapse
|
5
|
Kosak T, MacAusland S, Krishnan M, Orio P, Pashtan I, Peng L, Shiloh R, Tanguturi S, Warren L, Beaudette K, Cail D, Holdsworth C, Zanelli C, Phillips J. Prospective Peer Review for Patients Undergoing Stereotactic Body Radiation Therapy and Intracranial Radiosurgery in a Multi-Site Community-Setting is Both Feasible and Effective. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.1442] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
6
|
Bellon J, Chen Y, Rees R, Taghian A, Wong J, Punglia R, Shiloh R, Krishnan M, Andrews C, Isakoff S, Winer E, Tolaney S. A Prospective Phase I trial of Concurrent Cisplatin (CIS) and Radiation Therapy (RT) in Women with Stage II and III Triple-negative Breast Cancer (TNBC). Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.466] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
7
|
Shi D, Hertan L, Balboni T, Shiloh R, Warren L, Skamene S, Roper K, Apkon D, Chen Y, Krishnan M. Prospective Pilot Comparison Of Acute Gastrointestinal Toxicities And Quality Of Life Among Patients with Spinal Metastases Receiving Radiation Therapy Delivered with Three Planning Techniques. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.07.1296] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
8
|
Skamene S, Shi D, Krishnan M, Shiloh R, Warren L, Brown J, Apkon D, Roper K, Chen Y, Balboni T, Hertan L. Prospective Dosimetric Evaluation of Three Radiation Delivery Techniques for Spinal Metastases and Dosimetric Predictors of Gastrointestinal Toxicity. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.07.1297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
9
|
Shi D, Hertan L, Krishnan M, Skamene S, Shiloh R, Huynh M, Spektor A, Zaslowe-Dude C, Balboni T. Quantitative-Qualitative Analyses of Patient-Reported Pain Response after Palliative Radiation Therapy. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.07.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
10
|
Yerramilli D, Parker G, LeBaron V, Krishnan M, Hertan L, Spektor A, Shiloh R, Skamene S, Balboni T. Ethical Issues in the Care of Patients Referred for Palliative Radiation Therapy. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.543] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
11
|
Shi D, Hertan L, Balboni T, Shiloh R, Warren L, Skamene S, Roper K, Apkon D, Chen Y, Krishnan M. Prospective Pilot Comparison of Acute Gastrointestinal Toxicities and Quality of Life Among Patients with Spinal Metastases Receiving Radiation Therapy Delivered with Three Planning Techniques. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.1909] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
12
|
Krishnan M, Shiloh R, Dougherty P, Whitehouse C, Buckman A, Balboni T. The TEACHH Model: Clinical Utility of Identifying Patients Living Fewer Than 2 Months. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.485] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
13
|
Ber Y, Shiloh R, Gilad Y, Degani N, Bialik S, Kimchi A. DAPK2 is a novel regulator of mTORC1 activity and autophagy. Cell Death Differ 2014; 22:465-75. [PMID: 25361081 PMCID: PMC4326577 DOI: 10.1038/cdd.2014.177] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2014] [Revised: 08/19/2014] [Accepted: 08/21/2014] [Indexed: 12/15/2022] Open
Abstract
Autophagy is a tightly regulated catabolic process, which is upregulated in cells in response to many different stress signals. Inhibition of mammalian target of rapmaycin complex 1 (mTORC1) is a crucial step in induction of autophagy, yet the mechanisms regulating the fine tuning of its activity are not fully understood. Here we show that death-associated protein kinase 2 (DAPK2), a Ca(2+)-regulated serine/threonine kinase, directly interacts with and phosphorylates mTORC1, and has a part in suppressing mTOR activity to promote autophagy induction. DAPK2 knockdown reduced autophagy triggered either by amino acid deprivation or by increases in intracellular Ca(2+) levels. At the molecular level, DAPK2 depletion interfered with mTORC1 inhibition caused by these two stresses, as reflected by the phosphorylation status of mTORC1 substrates, ULK1 (unc-51-like kinase 1), p70 ribosomal S6 kinase and eukaryotic initiation factor 4E-binding protein 1. An increase in mTORC1 kinase activity was also apparent in unstressed cells that were depleted of DAPK2. Immunoprecipitated mTORC1 from DAPK2-depleted cells showed increased kinase activity in vitro, an indication that DAPK2 regulation of mTORC1 is inherent to the complex itself. Indeed, we found that DAPK2 associates with components of mTORC1, as demonstrated by co-immunoprecipitation with mTOR and its complex partners, raptor (regulatory-associated protein of mTOR) and ULK1. DAPK2 was also able to interact directly with raptor, as shown by recombinant protein-binding assay. Finally, DAPK2 was shown to phosphorylate raptor in vitro. This phosphorylation was mapped to Ser721, a site located within a highly phosphorylated region of raptor that has previously been shown to regulate mTORC1 activity. Thus, DAPK2 is a novel kinase of mTORC1 and is a potential new member of this multiprotein complex, modulating mTORC1 activity and autophagy levels under stress and steady-state conditions.
Collapse
Affiliation(s)
- Y Ber
- Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 76100, Israel
| | - R Shiloh
- Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 76100, Israel
| | - Y Gilad
- Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 76100, Israel
| | - N Degani
- Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 76100, Israel
| | - S Bialik
- Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 76100, Israel
| | - A Kimchi
- Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 76100, Israel
| |
Collapse
|
14
|
Shiloh R, Zemishlany Z, Aizenberg D, Weizman A. Sulpiride adjunction to clozapine in treatment-resistant schizophrenic patients: a preliminary case series study. Eur Psychiatry 2012; 12:152-5. [PMID: 19698523 DOI: 10.1016/s0924-9338(97)80205-2] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/27/1996] [Accepted: 10/09/1996] [Indexed: 11/19/2022] Open
Abstract
Six chronic neuroleptic-resistant schizophrenic patients, partial responders to clozapine, were co-administered 600 mg/day of sulpiride (a selective D(2) dopaminergic antagonist) as an augmentation to clozapine (a relatively weak D(2) blocker), for 10 weeks, open-labeled. A remarkable reduction in positive and negative symptoms was observed in four of the six patients.
Collapse
|
15
|
Shiloh R, Rakhra S, Evans J, Helenowski I, Kang Z, Mulcahy M, Small W, Hayes J. Retrospective Review of the Dosimetric and Treatment-Related Determinants of Toxicity in Patients with Esophageal Cancer Treated with Concurrent Chemoradiation with or without Surgery. Int J Radiat Oncol Biol Phys 2011. [DOI: 10.1016/j.ijrobp.2011.06.524] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
16
|
Shiloh R, Zemishlany Z, Aizenberg D, Valevski A, Bodinger L, Munitz H, Weizman A. Mianserin or placebo as adjuncts to typical antipsychotics in resistant schizophrenia. Int Clin Psychopharmacol 2002; 17:59-64. [PMID: 11890187 DOI: 10.1097/00004850-200203000-00003] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
The beneficial effect of atypical antipsychotic drugs (APDs) in treatment-resistant schizophrenia patients has been attributed, mostly, to their relatively high serotonergic (5-HT)2 to dopaminergic (D)2 receptor blockade ratio. We hypothesized that a combination of typical APDs (D2 antagonists) and mianserin, a potent 5-HT2 antagonist, might also exert superior efficacy in this population. Eighteen inpatients with treatment-resistant schizophrenia who had an acute psychotic exacerbation of the disorder received, in a double-blind design, 30 mg/day mianserin (n = 9) or placebo (n = 9) in conjunction with typical neuroleptics [haloperidol (n = 9) or perphenazine (n = 9)]. Clinical status was evaluated before, during, and at the end of 6 weeks of combined treatment with the Brief Psychiatric Rating Scale (BPRS), Scale for the Assessment of Positive Symptoms (SAPS), Scale for the Assessment of Negative Symptoms and Hamilton Rating Scale for Depression. The typical APD/mianserin group exhibited significantly greater improvement in total BPRS scores (17.6% versus 5.5%; P= 0.03) and a trend towards greater improvement in SAPS scores (35.3% versus 13.0%; P = 0.07). Our study indicates that patients with chronic treatment-resistant schizophrenia who have an acute psychotic exacerbation ('acute-on-chronic') may benefit from the addition of a potent 5-HT2 blocker, such as mianserin, to typical antipsychotics. Our findings may further emphasize the contribution of enhanced 5-HT2 blockade to the 'atypicality' of the atypical APDs and to their greater efficacy in alleviating symptoms of chronic treatment-resistant schizophrenia.
Collapse
Affiliation(s)
- R Shiloh
- Geha Psychiatric Hospital and Felsenstein Medical Research Center, Rabin Medical Center, Petah Tiqva, Israel.
| | | | | | | | | | | | | |
Collapse
|
17
|
Abstract
A case is presented in which severe urinary retention (UR) occurred during an acute psychotic exacerbation of paranoid schizophrenia. The voiding dysfunction was apparent during continuous treatment with unchanged doses of haloperidol, and it completely resolved with the remission of the psychotic symptoms. A clear temporal correlation was evident between the patient's mental status, the Brief Psychiatric Rating Scale (BPRS) score and the degree of the UR as assessed by quantitatively measuring the total daily post-voiding urine residues. We could not relate the UR to any apparent general medical condition or to the haloperidol treatment. The presented data suggests that UR in schizophrenic patients might be the end-result of various psychosis-related mechanisms.
Collapse
Affiliation(s)
- R Shiloh
- Geha Psychiatric Hospital, Felsenstein Medical Research Center, Rabin Medical Center, Beilinson Campus, Petah Tiqva, Israel.
| | | | | | | | | |
Collapse
|
18
|
Gil-ad I, Shtaif B, Shiloh R, Weizman A. Evaluation of the neurotoxic activity of typical and atypical neuroleptics: relevance to iatrogenic extrapyramidal symptoms. Cell Mol Neurobiol 2001; 21:705-16. [PMID: 12043843 DOI: 10.1023/a:1015152021192] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Typical neuroleptic therapy often results in extrapyramidal symptoms (EPS) and tardive dyskinesia (TD). Recent reports reveal neurotoxic activity in some neuroleptics. We hypothesized that neurotoxicity might be implicated in EPS. This study aims to evaluate the neurotoxic activity of typical and atypical neuroleptics and to determine the possible role of neurotoxicity in neuroleptic-induced EPS. Perphenazine, haloperidol, clozapine, sulpiride, and risperidone (10-100 microM) were administered, either alone or combined with dopamine, to primary mouse neuronal or intact brain culture and to a human neuroblastoma (NB) cell line (SK-N-SH). Cell viability (measured by neutral red and alamar blue), DNA fragmentation (flow cytometry-NB) were determined. Neuroblastoma: perphenazine, clozapine, and haloperidol (100 microM) decreased viability by 87, 43, and 34% respectively. Sulpiride and risperidone were not toxic. At 10 microM, toxicity decreased markedly. Dopamine (125 microM) potentiated the perphenazine-induced toxicity. Flow cytometry of NB cells treated with perphenazine (2.5-40 microM) showed an increase (perphenazine 20 microM, 40 microM, 48 h) in fragmented DNA (74.7% and 95.0% vs. 8.7% in controls). Lower concentrations increased the G1 phase and decreased S phase in the cell cycle. In primary neurons, perphenazine, haloperidol, and clozapine, but not risperidone and sulpiride, induced a significant neurotoxic effect, which, in intact brain culture, was absent (haloperidol and clozapine) or lowered (perphenazine). Dopamine (0.5 mM) did not modify the effect of the drugs in the primary cultures. Neuroleptics possess differential neurotoxic activity with higher sensitivity of neoplasm tissue (NB compared to primary cultures). The order of toxicity was perphenazine > haloperidol = clozapine:sulpiride and risperidone were not toxic. Neurotoxicity is independent of dopamine and is associated with cell cycle arrest and apoptosis. With the exception of clozapine, neurotoxicity seems relevant to neuroleptic-induced EPS and TD.
Collapse
Affiliation(s)
- I Gil-ad
- Laboratory of Biological Psychiatry, Felsenstein Medical Research Center, Tel-Aviv University, Petah-Tiqva, Israel
| | | | | | | |
Collapse
|
19
|
Shiloh R, Porat DY, Weizman A, Munitz H. [Eosinophilia as an unfavorable prognostic factor for clozapine-induced severe adverse side-effects]. Harefuah 2001; 140:1058-61. [PMID: 11759382] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
|
20
|
Valevski A, Ratzoni G, Sever J, Apter A, Zalsman G, Shiloh R, Weizman A, Tyano S. Stability of diagnosis: a 20-year retrospective cohort study of Israeli psychiatric adolescent inpatients. J Adolesc 2001; 24:625-33. [PMID: 11676509 DOI: 10.1006/jado.2001.0423] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Outcome according to diagnosis and stability of diagnosis were investigated in a follow-back study of 351 adolescents with various psychiatric disorders hospitalized in a closed psychiatric ward. The duration of follow-back was 15-19 years. All diagnoses were based on the ICD-9. Data were collected from the Health Ministry registry and, in the patients who could be located, by structured telephone interview. Special attention was directed at the diagnosis of transient adolescent psychosis (TAP) vs. schizophrenia and prognostic indicators of suicide. The results showed that the most stable diagnosis was anxiety disorder. The stability of the different diagnoses over time was greater between the second and last admission than between the first and last (for patients with three or more admissions). Number of hospitalizations correlated negatively with prognosis. TAP at second admission was an unstable diagnosis; 66% of these patients had a final diagnosis of schizophrenia. However, patients with a diagnosis of TAP at first admission had a higher predictive index score and a higher outcome score than schizophrenic patients. TAP appeared to be a valid diagnostic entity, distinguishable from schizophrenia in course, frequency of suicidal behaviour and social-occupational outcome. Suicide victims had a higher cumulative length of stay than age- and sex-matched non-suicidal patients. Fifty per cent of the suicide victims had a final diagnosis of schizophrenia, compared to 30 per cent for the whole sample. In conclusion, these findings indicate that TAP is associated with a relatively good prognosis and should probably be differentiated from schizophrenia. Further retrospective and prospective studies of adolescent psychiatric inpatients may help delineate the nature and course of psychosis and other psychopathology in this age group.
Collapse
Affiliation(s)
- A Valevski
- Geha Psychiatric Hospital, Petah Tiqva, Israel
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Shiloh R, Weizman A, Epstein Y, Rosenberg SL, Valevski A, Dorfman-Etrog P, Wiezer N, Katz N, Munitz H, Hermesh H. Abnormal thermoregulation in drug-free male schizophrenia patients. Eur Neuropsychopharmacol 2001; 11:285-8. [PMID: 11532382 DOI: 10.1016/s0924-977x(01)00096-7] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Schizophrenia patients may develop various thermoregulatory disturbances. We hypothesized that a standardized exercise-heat tolerance test [two 50-min bouts of walking a motor-driven treadmill at 40 degrees C (relative humidity=40%)] would reveal abnormal thermoregulation in drug-free schizophrenia patients. Six drug-free schizophrenia outpatients and seven healthy comparison subjects participated in this study. The schizophrenia patients exhibited significantly higher baseline and exertion-related rectal temperature. The relevance of these findings to the pathophysiology of schizophrenia-related thermoregulatory disorders is as yet unclear.
Collapse
Affiliation(s)
- R Shiloh
- Geha Psychiatric Hospital, Felsenstein Medical Research Center, Beilinson Campus, Petah Tiqva, Israel
| | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Berger E, Shiloh R, Weizman A, Munitz H. [Possible relevance of alterations at the cellular, neuronal connectivity and brain structure levels to the pathophysiology of schizophrenia]. Harefuah 2001; 140:648-52. [PMID: 11481973] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
|
23
|
Shiloh R, Weizman A, Weizer N, Dorfman-Etrog P, Munitz H. [Antidepressive effect of pyridoxine (vitamin B6) in neuroleptic-treated schizophrenic patients with co-morbid minor depression--preliminary open-label trial]. Harefuah 2001; 140:369-73, 456. [PMID: 11419053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Abstract
BACKGROUND Minor depression is reported in 20-60% of schizophrenic patients during various stages of their disorders; impairing patients' compliance, response to treatment and worsening their overall prognosis. Various anti-depressive treatments have been proposed for such cases but response rates are usually poor. Pyridoxine (Vitamin B6) in essential for the proper metabolism of various neurotransmitters that are considered relevant to the pathophysiology of depression and/or schizophrenia and it has been reported beneficial in ameliorating depressive symptoms as part of major depression, premenstrual syndrome or 'Chinese restaurant syndrome'. We hypothesized that addition of pyridoxine to on-going neuroleptic treatment could improve minor depression in schizophrenic patients. METHOD Nine schizophrenic patients with co-morbid minor depression participated in this study. All participants had a stable unchanged clinical state (changes in Brief Psychiatric Rating Scale (BPRS). Scale for the Assessment of Positive Symptoms (SAPS), and Scale for the Assessment of Negative symptoms (SANS) scores < 5%) and all were maintained on unchanged doses of anti-psychotic drugs for at least 4 consecutive weeks prior to initiation of the study. Participants received, open-label, pyridoxine 150 mg/day in addition to their anti-psychotic treatment for 4 consecutive weeks. Mental status was evaluated before, during, and at the end of 4 weeks of pyridoxine administration using the BPRS, SAPS, SANS and HAM-D. RESULTS Two of the nine patients (22%), characterized by higher initial HAM-D and SANS scores, and by older age and longer duration of illness, experienced marked improvements in depressive symptoms (23% and 28% decrease in HAM-D scores) following 4 weeks of pyridoxine administration. In one of these two, the improvement in depressive symptoms was accompanied by a parallel decrease in SANS Scores. CONCLUSION A subgroup of schizophrenic patients with comorbid minor depression may benefit from pyridoxine addition to their on-going anti-psychotic treatment.
Collapse
Affiliation(s)
- R Shiloh
- Geha Psychiatric Hospital, Felsenstein Medical Research Center, Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel
| | | | | | | | | |
Collapse
|
24
|
|
25
|
Hermesh H, Manor I, Shiloh R, Weizman R, Munitz H. Absence of myoglobinuria in acute psychotic patients with marked elevation in serum creatine phosphokinase level. Eur Neuropsychopharmacol 2001; 11:111-5. [PMID: 11313156 DOI: 10.1016/s0924-977x(00)00139-5] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Elevated levels of serum creatine phosphokinase, muscular type (CK(MM)) are caused primarily by diseased muscle fiber. Acute psychoses are often associated with a marked increase in serum CK(MM) levels, though the reason remains obscure. Since striated muscle damage is also associated with pigmenturia and myoglobinuria, we sought to determine whether the markedly high serum CK level of acute psychosis reflects skeletal muscle damage by evaluating urinary myoglobin in affected patients. Baseline serum CK was measured on admission in 713 consecutive acute psychotic inpatients (BPRS> or =40). Those showing a serum CK levels above 1000 IU/l on the first 2 days of hospitalization underwent urine collection for myoglobin testing. Patients with physical trauma or medical conditions known to cause CKemia were excluded. Twenty-five patients were eligible for the study. In no case did myoglobinuria or pigmenturia accompany the marked CKemia. There is an unexpected dissociation between the robust increase in the serum CK(MM) levels and the absence of myoglobinuria in acute psychosis. Our negative finding may indicate that the serum CK threshold for myoglobinuria is very high (above 10000 IU/l). Alternatively, psychosis-associated CKemia may be related to an unknown, nontraumatic, pathophysiological mechanism(s).
Collapse
Affiliation(s)
- H Hermesh
- Geha Psychiatric Hospital, Rabin Medical Center, Beilinson Campus, P.O. Box 102, 49100, Petach Tiqva, Israel.
| | | | | | | | | |
Collapse
|
26
|
Shiloh R, Hermesh H, Weizer N, Dorfman-Etrog P, Weizman A, Munitz H. Acute antipsychotic drug administration lowers body temperature in drug-free male schizophrenic patients. Eur Neuropsychopharmacol 2000; 10:443-5. [PMID: 11115733 DOI: 10.1016/s0924-977x(00)00106-1] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
We examined, in a controlled design, potential alterations in body temperature of male schizophrenic patients following acute antipsychotic drug (APD) administration. Fourteen drug-free (study group) and seven schizophrenic patients maintained on APDs (comparison group) initiated or received higher dose of their APD, respectively, for 27 days. Initial body temperature was 0.36 degrees C higher in the study group (P=0.01) and decreased within 24 h to values comparable to that of the comparison group (all within normal range).
Collapse
Affiliation(s)
- R Shiloh
- Geha Psychiatric Hospital, Felsenstein Medical Research Center, Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel
| | | | | | | | | | | |
Collapse
|
27
|
Abstract
OBJECTIVE Schizophrenia may be associated with hyperthermic syndromes such as febrile catatonia, neuroleptic malignant syndrome, and heatstroke. The authors hypothesized that an exercise-heat tolerance test would disclose abnormal thermoregulation in schizophrenic patients. METHOD Seven male schizophrenic outpatients in remission maintained on depot antipsychotic treatment and eight healthy comparison subjects completed a heat tolerance test that consisted of two 50-minute bouts of walking a motor-driven treadmill at 40xC (relative humidity=40%). RESULTS A significantly higher rise in rectal and skin temperatures was observed in the patient group. No differences in heart rate, blood pressure, or perspiration were detected. CONCLUSIONS Schizophrenic patients maintained on antipsychotic drugs exhibit impaired heat tolerance. Possible explanations are a reduced ability to convey heat from the body's core to the periphery with or without excessive heat production. The hyperthermic response to the heat tolerance test may reflect a dysfunction associated with schizophrenia, a neuroleptic-induced side effect, or both.
Collapse
Affiliation(s)
- H Hermesh
- Geha Psychiatric Hospital, Petah Tiqva, Israel.
| | | | | | | | | | | |
Collapse
|
28
|
Shiloh R, Zemishlany Z, Aizenberg D, Radwan M, Schwartz B, Dorfman-Etrog P, Modai I, Khaikin M, Weizman A. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br J Psychiatry 1997; 171:569-73. [PMID: 9519099 DOI: 10.1192/bjp.171.6.569] [Citation(s) in RCA: 186] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
BACKGROUND We hypothesised that a combined regimen of clozapine, a relatively weak D2-dopaminergic antagonist, and sulpiride, a selective D2 blocker, would demonstrate a greater antipsychotic efficacy by enhancing the D2 blockade of clozapine. METHOD Twenty-eight people with schizophrenia, previously unresponsive to typical antipsychotics and only partially responsive to current treatment with clozapine, received, double-blind, 600 mg/day sulpiride or placebo, in addition to an ongoing clozapine treatment. The clinical status was evaluated before, during, and at the end of 10 weeks of sulpiride addition using the Brief Psychiatric Rating Scale (BPRS), Scale for the Assessment of Positive Symptoms (SAPS), Scale for the Assessment of Negative Symptoms, and Hamilton Rating Scale for Depression. RESULTS The clozapine-sulpiride group exhibited substantially greater and significant improvements in positive and negative psychotic symptoms. About half of them, characterised by a younger age and lower baseline SAPS scores, had a mean reduction of 42.4 and 50.4% in their BPRS and SAPS scores, respectively. CONCLUSIONS A subgroup of patients with chronic schizophrenia may substantially benefit from sulpiride addition to clozapine.
Collapse
Affiliation(s)
- R Shiloh
- Geha Psychiatric Hospital, Rabin Medical Center, Petah Tiqva, Israel
| | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Abstract
Male orgasmic disorder is commonly encountered among patients treated with thioridazine. This side effect interferes significantly with sexual satisfaction. In this pilot study, eight male schizophrenic patients who complained of orgasmic disorder, compatible with probable retrograde ejaculation during thioridazine treatment, were given concomitant low-dose imipramine (25-50 mg at bedtime). Four of the eight reported complete resumption of their previous ejaculatory function, and in one patient there was a partial, but substantial, improvement. Three patients noted no change. It appears that imipramine might be beneficial for some patients with thioridazine-induced male orgasmic disorder.
Collapse
Affiliation(s)
- D Aizenberg
- Geha Psychiatric Hospital, Rabin Medical Center, Petah Tiqva, Israel
| | | | | | | |
Collapse
|
30
|
Abstract
A patient with posttraumatic stress disorder (PTSD) had several episodes of catatonia in the past 44 years. These episodes were characterized by a sudden onset of intense excitement, mild pyrexia, often moderate elevation of serum creatinine phosphokinase and the development of a full catatonic state. We could not relate the symptomatology exhibited to any one of the accepted etiologies of catatonia. We assume, following careful evaluation of the clinical picture, and thorough biochemical and imaging work-up, that in this case the catatonic states represented an overwhelming psychic response to associated traumatic recollections, bringing to extreme the avoidance, numbness and motor responses usually encountered in PTSD.
Collapse
Affiliation(s)
- R Shiloh
- Beilinson Medical Center, Geha Psychiatric Hospital, Petah Tiqva, Israel
| | | | | | | |
Collapse
|
31
|
Kuhl P, Shiloh R, Jha H, Murawski U, Zilliken F. 6,7,4'-Trihydroxyisoflavan: a potent and selective inhibitor of 5-lipoxygenase in human and porcine peripheral blood leukocytes. Prostaglandins 1984; 28:783-804. [PMID: 6441190 DOI: 10.1016/0090-6980(84)90035-2] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
The effect of 6,7,4'-trihydroxyisoflavan on human platelet 12-lipoxygenase and human and porcine PMNL 5-lipoxygenase activities has been studied. 6,7,4'-Trihydroxyisoflavan was found to inhibit 5-lipoxygenase more strongly than 12-lipoxygenase; its concentration for 50% inhibition (IC50) was 1.6 microM for human and porcine 5-lipoxygenase and 22 microM for human platelet 12-lipoxygenase. Inhibition of microsomal cyclooxygenase from ram seminal vesicles is exhibited at much higher concentrations of 6,7,4'-trihydroxyisoflavan (IC50 = 200 microM).
Collapse
|
32
|
Wapnick S, Solowiejczyk M, Shiloh R, Grosman E. Detection of intestinal ischemia. I. Microradiological and temperature differences between mesenteric and antimesenteric margin of the small intestine of the rat. J Surg Res 1976; 21:403-7. [PMID: 1011820 DOI: 10.1016/0022-4804(76)90164-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|